Keros Therapeutics Inc (KROS) Company Profile & Statistics

Keros Therapeutics Inc
KROS
(Nasdaq - US)
Closed
56.55
-3.80 (-6.30%)
in:usd•As of: Nov 15, 2024 15:59 UTC -5
Pre Market:0+0.00 (0.00%)
Open
60.30
High
60.30
Low
55.24

About Keros Therapeutics Inc

CEO

Jasbir Seehra

Headquarters

1050 waltham street, suite 302

lexington, ma 02421, united states

Auditor

Deloitte & Touche LLP

Employees

136

Share Holders

Website

www.kerostx.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel treatments for hematological and musculoskeletal disorders. The company's product pipeline consists of KER-050, KER-047and KER-012 which are in clinical stage. Keros Therapeutics, Inc. is based in LEXINGTON, MA.

Keros Therapeutics Inc Statistics

Valuation Measures

Market Capitalization ²	2.29B
Enterprise Value	1.88B
Enterprise Value/EBITDA (ttm)	-10.05
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	4.30
Price to Sales (ttm)	3.52K
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	100.00%
Operating Margin (ttm)	-27890.94%
Profit Margin (ttm)	-173850.66%
Return on Equity (ttm)	-41.74%
Return on Invested Capital (ttm)	-45.69%
Return on Assets (ttm)	-38.42%

Income Statement

Revenue (ttm)	271.00K
Revenue Per Share (ttm)	0.01
Gross Profit (ttm)	271.00K
EBITDA (ttm)³	-187.62M
Net Income Avi to Common (ttm)	-168.05M
Diluted EPS (ttm)	-5.21

Share Statistics

Beta (5Y Monthly)	1.23
52-Week Change	88.50%
S&P500 52-Week Change	29.10%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	37.52M
Dividend Yield	0.00%
Float ⁴	31.23M
% Held by Insiders	22.90%
% Held by Institutions	71.56%

Balance Sheet

Total Cash (mrq)	405.86M
Total Cash Per Share (mrq)	10.82
Total Debt (mrq)	0.00
Total Debt/Equity (mrq)	0.00%
Current Ratio (mrq)	20.37%
Quick Ratio (mrq)	19.03%
Book Value Per Share (mrq)	11.64

Cash Flow

Operating Cash Flow Per Share (ytd)	-2.34
Free Cash Flow (ytd)	-85.62M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Keros Therapeutics Inc

Trade With A Regulated Broker